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Despite limited evidence on safety and efficacy of drug use in neonates, drugs
are extensively used in this age group. However, the availability of information on
drug consumption in neonates, especially inpatient neonates, is limited. This paper
systematically reviews published studies on drug utilization in hospitalized neonates. A
systematic literature review was carried out to identify observational studies published
from inception of databases used till August 2016. Four search engines, namely
Medline, CINAHL, Embase, and PubMed, were used. Publications written in English
that described drug utilization in neonatal wards were selected. Assessment of the
data was based on the category of the study design, the objective of study and the
method used in reporting drug consumption. A total of 20 drug utilization studies were
identified, 12 of which focused on all drug classes, while the other eight evaluated
antimicrobials. Studies were reported in Europe (n = 7), the United States (n = 6),
India (n = 5), Brazil (n = 1), and Iran (n = 1). Substantial variance with regard to study
types (study design and methods), data source, and sample size were found among the
selected studies. Of the studies included, 45% were cross-sectional or retrospective,
40% were prospective studies, and the remaining 15% were point prevalence surveys.
More than 70% of the studies were descriptive studies, describing drug consumption
patterns. Fifteen per cent of the descriptive studies evaluated changes in drug utilization
patterns in neonates. Volume of units was the most prevalent method used for reporting
all drug categories. The ATC/DDD system for reporting drug use was only seen in
studies evaluating antimicrobials. The most commonly reported drugs across all studies
are anti-infectives for systemic use, followed by drugs for the cardiovascular system,
the nervous system and the respiratory system. Ampicillin and gentamicin were the
most prescribed antimicrobials in hospitalized neonates. The present review reveals that
neonates are exposed to a high number of drugs and various methods are used to report
drug consumption in this age group. The best measure of drug consumption to quantify
prevalence of drug use in neonates remains to be identified and additional research in
this area is warranted.
Keywords: health services administration, drug utilization review, hospital central supply, daily defined dosage,
drug dosage calculations
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INTRODUCTION
The World Health Organization (WHO) defined Drug
Utilization Research (DUR) as research into the marketing,
distribution, prescription, and use of drugs in society, with
special emphasis on the resulting medical, social, and economic
consequences (World Health Organization, 2003). Besides
describing patterns of drug consumption, DUR can also be used
to identify problems related to drugs that deserve more research
in various health care settings. Drug utilization monitoring can
be used to assess the rational use of drug therapy when data
on drug use is correlated with figures on morbidity, outcome
of treatment (effectiveness in clinical and economic terms)
and quality of care (Zuppa et al., 2007; Wettermark et al.,
2016).
As monitoring of drug consumption can identify problems
related to drug therapy, evidence from DUR is essential to
create awareness about irrational drug use by giving feedback to
physicians and recommending measures to improve prescribing
behavior (Chatterjee et al., 2007; Sequi et al., 2013). Rational and
appropriate prescribing is especially crucial for neonates due to
their non-fully developed organ functions and the small body
size that predisposes them to drug toxicity if an overdose occurs.
Most of the drugs in the market were not tested for use in this
age group as neonates were often excluded during clinical trials.
Therefore, there is limited information on the safety and efficacy
of drugs used to treat this population (Smyth and Weindling,
1999; Chatterjee et al., 2007; Sammons, 2011; Nor Aripin et al.,
2012; Sequi et al., 2013).
Neonates, particularly from high-risk pregnancies, often
present with multiple co-morbidities due to immature organs,
which may necessitate intensive and complex medical care
with high exposure to drugs. Due to limited clinical trial
data among neonates, pediatricians extrapolate suitable drug
dosing from adult patients leading to unlicensed or off-
label use of drugs among neonates (Sanghera et al., 2006;
Awaisu and Sulaiman, 2007; Sturkenboom et al., 2008; Dessi
et al., 2010; Neubert et al., 2010; Lass et al., 2011; Booth
et al., 2012; Kimland and Odlind, 2012; Ballard et al., 2013).
Advances in neonatology have not only improved the survival
of neonates but have contributed to dynamic changes in the
drug utilization profile in neonates, both in the number of
drugs and the pharmacotherapeutic groups (Clark et al., 2006;
Warrier et al., 2006; Chatterjee et al., 2007; Hsieh et al.,
2014). Despite the advances in this area, there is a paucity
of information on drug utilization in neonatals, particularly
in the hospital setting (Du et al., 2006; Neubert et al.,
2010).
To the best of our knowledge, only a handful of systematic
reviews have been conducted to evaluate drug utilization in
the pediatric population, and these are mainly focused on
outpatient settings. A review by Clavenna and Bonati evaluated
128 studies of pediatric drug utilization in outpatient settings
published between January 1994 and December 2008, whilst
others reviewed drug utilization of specific drug classes (e.g.,
antibiotics, anti-asthmatics, and antidepressants, Rossignoli et al.,
2007; Clavenna and Bonati, 2009; Bianchi et al., 2010). Other
reviews reported statistical methods performed in DUR using
the same studies included in the previous review by Clavenna
and Bonati (2009) and updated the literature search up to
December 2011 (Clavenna and Bonati, 2009; Sequi et al., 2013). A
global extant literature search confirms a gap in current medical
knowledge. Thus, the aim of this review is to determine the drug
prescribing patterns for neonates in hospital, with a focus on
the most common therapeutic class prescribed, and to evaluate
different methodologies used in reporting drug consumption in
hospitalized neonates. A search of the literature was therefore
performed to explore the drug utilization profile for inpatient
neonates.
METHODS
Search Strategy
A systematic search was performed in August 2016 on Medline
(1946–2016), CINAHL (1937–2016), Embase (1947–2016), and
PubMed (1996–2016) for all articles written in English reporting
on drug utilization in neonatal wards from inception of the
database to August 2016. The search was restricted to human
studies and those that described drug utilization or drug
patterns or trends. The Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) flowchart (Figure 1) and
a PRISMA checklist (Refer to S1 PRISMA Checklist) are used to
illustrate the electronic search progression of this study (Moher
et al., 2009).
Search Terms
The search was performed using the Boolean operators (“AND”
& “OR”) with a combination of neonate(s) or newborn, infants
with the following key words: drug utilization, defined daily
dose(s), prescribed daily dose(s), and anatomical therapeutic
chemical classification (ATC). The detailed search strategies
used to retrieve articles from the databases are shown in
Table 1.
Inclusion Criteria
Studies were included if they reported any measures of drug
consumption: drug volume or expenditure, Defined Daily Doses
(DDD), Prescribed Daily Doses (PDD), and categories of
drugs (Anatomical Therapeutic Chemical Classification (ATC).
The age categories for studies to be selected was defined on
the basis of the International Conference on Harmonisation
Guidelines on the Clinical Investigation of Medicinal Products
in the Paediatric Population: neonates ≤ 27 days and infants
≤ 23 months (International Conference on Harmonisation of
Technical Requirements for Registration of Pharmaceuticals for
Human Use, 2014). Another inclusion criterion is infants in
the neonatal wards, as there were critically ill neonates who
required medical support, which consequently led to longer
stays in the neonatal ward, meaning that the children surpassed
their neonatal age. Studies on drug utilization in the general
hospitalized pediatric population were only included if neonate
drug consumptions were reported separately from other age
groups and the patterns of drug use in the neonates were
determined.
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FIGURE 1 | Flow chart of the systematic review.
Exclusion Criteria
Reviews, editorials, comments, clinical trials, book chapters,
conference abstracts, and other studies relating to other age
categories including children (2–11 years old), adolescents
(12–17 years old), and adults (≥18 years old) were excluded.
Studies related to a higher age limit (>23 months) and
those involving outpatient children or children attending
emergency departments were excluded due to the high
possibility of variation with regard to medical conditions and
pharmacotherapy prescribed. Studies evaluating adverse drug
reactions, costs or health-care resource utilization were excluded.
Selection of the Studies
After the removal of duplicates, the identified publications
were manually screened on the basis of titles and abstracts.
Observational studies identified as containing potentially
relevant information were subsequently reviewed as full-text
articles. To further enhance the search, the reference lists
of the selected publications were checked for other relevant
publications that might meet the study eligibility criteria.
Unpublished or gray literature was excluded.
The selected full-text articles were evaluated for relevancy and
quality of study design. In order to assess the risk of potential
bias, the quality of selected studies was assessed using 14 criteria
of the Quality Assessment tool for Observational Cohort and
Cross-sectional Studies proposed by National Institutes of Health
(United States), 2016. For each item on the tool, the reviewer
could select “yes,” “no,” or “cannot determine/not reported/not
applicable.” The potential risk of bias was considered if “no” or
“cannot determine/not reported/not applicable” were selected for
the items by the reviewer. Reviewers then rated the quality of the
study as “good,” “fair,” or “poor.” Studies that were categorized
as “good” have the least risk of bias’ “fair” studies have an
intermediate risk of bias. Studies with a “poor” rating had a
significant risk of bias and were thus excluded from further
evaluation. Meta-analysis was not performed as the studies
retrieved were heterogeneous and were all observational study
designs.
Data Extraction
A data extraction sheet was designed to guide the evaluation
process of the selected articles and to capture information
on the variables of interest. The eligibility assessment was
performed independently by two reviewers. The first reviewer,
indicated as RR, screened titles and abstracts, and checked the
eligibility of abstracts and full text after initial screening for
data extraction. A second reviewer, indicated as LCM, checked
the information tabulated in the data synthesis matrix with the
full text articles included in the review. The eligibility of the
studies included was also assessed by the second reviewer and
there were no disagreements in eligibility assessment between
the two reviewers. Details of study design, study objectives,
study population and sample size, study setting, methods on
quantifying drug consumption, and the main findings were
extracted from the articles. If available, information on the
interventions or recommendations to improve reporting or
rational drug use was also retrieved.
RESULTS
Search Results
The initial search of the four databases resulted in the retrieval
of 4389 articles. However, due to the duplication of articles
retrieved fromCINAHL, Embase, and PubMed from those found
through Medline, almost all articles from these search engines
were excluded from the study. As shown in Figure 1, after the
screening of the titles and abstract, 52 articles remained for
further evaluation of the full text. Out of the 52, the following
were not considered for in-depth analysis of drug utilization:
studies that involved neonates or infants with particular
conditions (n = 1); studies evaluating off-label/unlicensed drug
use (n = 3); studies analyzing drug use of a specific drug(s)
(n = 8) or a category of drug (excluding antimicrobials)
(n= 13); studies analyzing drug use in comparison with the drug
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TABLE 1 | Search strategy used to search publications from databases.
Keywords Search engines Results Chosen
(“drug utilization” OR “drug utilisation” OR “defined daily dose*” OR “prescribed daily
dose*” OR “anatomical therapeutic chemical classification”) AND (“infant*” OR “neonate*”
OR “newborn”)
Ovid (Medline) 1060 42
drug utilization OR drug utilisation OR defined daily dose OR prescribed daily dose OR
anatomical therapeutic chemical classification AND infant OR neonate OR newborn
EBSCHO host (CINAHL Plus) 365 0
drug NEXT/2 utilisation OR “prescribed daily dose*” OR “defined daily dose*” OR
“anatomical therapeutic chemical classification” AND “neonate*” OR “newborn”/exp OR
“newborn” OR “infant”/exp OR ‘infant”
Embase 621 4
(drug utilization OR drug utilisation OR defined daily dose OR prescribed daily dose OR
anatomical therapeutic chemical classification) AND (infant OR neonate OR newborn)
PubMed 2289 0
expenditure (n= 2); and studies on drug utilization in the general
pediatric population (n= 3).
The remaining 20 articles were included in the review
(Medline, n = 14, and Embase, n = 2, and from manual
searching through other databases, World of Science, n = 3,
and Google Scholar, n = 1). Out of the 20 selected articles, 12
studies evaluated all drug categories in neonates, whilst the others
evaluated antimicrobials used in neonates. Studies evaluating
antimicrobials were included as these agents were the most
commonly prescribed in neonates. Three articles (Kumar et al.,
2008; Neubert et al., 2010; Lass et al., 2011) partly evaluating
unlicensed drug/off-label use were included as these studies
also reported overall drug consumption in neonates. For drug
utilization study on antibiotics, four studies involved other
pediatric age groups (Grohskopf et al., 2005; Zingg et al., 2011;
Porta et al., 2012; Salehifar et al., 2014). No articles related to
drug utilization in neonates were found from cross-reference of
the bibliographies of the full-text articles selected.
Quality of Studies
A quality assessment of the selected studies indicated that 15%
(n = 3) were poor quality, 45.0% (n = 9) were fair, and
40.0% (n = 8) were of good quality. The National Institutes
of Health Quality Assessment guidelines recommend excluding
poor-quality articles from further analysis. However, in this
review, these articles were included as the total number of
retrieved articles was low (n= 20).
Characteristics of the Drug Utilization
Studies
The general characteristics of selected studies included are
summarized in Table 2. Of the 20 selected articles, 35% (n = 7)
were from Europe [Estonia (n = 1), Germany (n = 1), Poland
(n = 2), Switzerland (n = 1), the Netherlands (n = 1), and
Multinational (n = 1) (Greece, United Kingdom, Italy)] 30%
were from the United States (n = 6), 25% were from South Asia
(India, n = 5) and single studies reported on South America
(Brazil) and the Middle East (Iran). No publications related to
drug consumption in neonates from other regions, including
Southeast Asia, were identified. The distribution of studies was
uneven over a 12-year period (2005–2016), with only six studies
published from 2005 to 2008. 70% (n = 14) of the studies were
published from 2010 onwards. The observation periods ranged
from 1996 to 2014, with the study duration ranging from 2 days
to 9.3 years.
Overall, eight studies were prospective (3 cohort studies),
9 were cross-sectional or retrospective (2 cohort studies), and
two were point prevalence surveys. We failed to determine the
kind of study design of one article, and we deemed it as poor
quality. The data sources were mainly medical records or patient
charts and/or prescriptions (n = 9), followed by administrative
databases that were part of periodical health care monitoring
systems (n = 5) and pharmacy purchase databases (n = 3).
Other studies utilized standardized questionnaires (n = 1) and
pharmacy dispensing databases (n = 1). Studies using data
derived from a database were mainly retrospective in nature,
with a longer period of study coverage, ranging from 1 year
to 9.3 years. On the other hand, studies conducted using data
from patient medical records and drug prescriptions that were
conducted prospectively had shorter study coverage, ranging
from 3 months to 1 year. Others were point prevalence surveys
using questionnaires and prescriptions, which were carried out
in 2 and 14 days respectively, and a study using patients’ charts,
with a coverage of 7.7 years.
Objectives of Selected Studies
A majority of the selected studies (70%) aimed to describe
drug consumption patterns, with 15% of the studies evaluating
changes in drug utilization patterns in neonates. Other objectives
include evaluation of licensing status or off-label use of drugs
(15%), determination of future research areas (10%) and
evaluation of the impact of intervention (10%). The full list of
objectives is shown in Table 3. Some of the studies hadmore than
one objective.
Methods Used in Drug Utilization Studies
As shown in Table 4, a variety of methods were used in the
selected studies to present data on drug utilization. Some studies
utilized more than one method. More than half of the selected
studies, mainly describing drug consumption for all category
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TABLE 3 | Study objectives of the selected studies.
Study objectives Studies
n* % References
Drug utilization review 14 70 Grohskopf et al., 2005; Clark et al., 2006; Warrier et al., 2006; Chatterjee et al., 2007; Kumar
et al., 2008; Liem et al., 2010b; Neubert et al., 2010; Lass et al., 2011; Nitsch-Osuch et al.,
2013; Salehifar et al., 2014; Goncalves et al., 2015; Sharanappa et al., 2015; Subash and
Shanmugapriyan, 2015; Suryawanshi et al., 2016
Changes in drug utilization pattern 3 15 Clark et al., 2006; Du et al., 2006; Hsieh et al., 2014
Licensing status/ off label use 3 15 Kumar et al., 2008; Neubert et al., 2010; Lass et al., 2011
Determination of critical area for future research 2 10 Warrier et al., 2006; Neubert et al., 2010
Study impact of intervention 2 10 Zingg et al., 2011; Nitsch-Osuch et al., 2015
Drug utilization review and ADRs 1 5 Patel Brijal et al., 2015
Association of perinatal care, clinical care and drug use 1 5 Goncalves et al., 2015
Development of methodology 1 5 Porta et al., 2012
Evaluation of different methods in reporting 1 5 Clark et al., 2006
*Some studies had more than one objectives, although 20 studies were selected, information was extracted on objectives was 28 and percentages do not add up to 100%.
of drugs, reported the prevalence of drug used in terms of the
number of patients or prescriptions, which stated as either count,
courses, exposure, or exposure rate. Interestingly, three studies
from India reported drug consumption in neonates using WHO
core prescribing indicators (Chatterjee et al., 2007; Patel Brijal
et al., 2015; Suryawanshi et al., 2016).
Table 4 shows that the ATC/DDD system was only used in
three studies evaluating antibiotics (Liem et al., 2010b; Porta
et al., 2012; Nitsch-Osuch et al., 2013). Two studies used the DDD
system without ATC classification, whereas one study reported
antibiotics consumption using Days of Therapy (Zingg et al.,
2011; Salehifar et al., 2014; Nitsch-Osuch et al., 2015). Only one
study reported antibiotics consumption using the PDD system
(Porta et al., 2012). In addition, DU90 or DU100% was used as
one of the reporting methods in four studies evaluating antibiotic
utilization (Liem et al., 2010b; Porta et al., 2012; Nitsch-Osuch
et al., 2013, 2015).
For drug classification, only five studies evaluating all
drugs utilized ATC for drug classification, whilst others
used non-standardized classification of pharmacological groups
(Chatterjee et al., 2007; Neubert et al., 2010; Lass et al., 2011;
Goncalves et al., 2015; Suryawanshi et al., 2016). A few studies
reported specific drugs commonly prescribed for neonates
instead of using a drug classification system for reporting
(Grohskopf et al., 2005; Clark et al., 2006; Warrier et al.,
2006; Hsieh et al., 2014; Sharanappa et al., 2015; Subash and
Shanmugapriyan, 2015).
Prescribing Pattern
The most commonly reported drugs across all selected studies
were anti-infectives for systemic use, followed by drugs for the
cardiovascular system, the nervous system and the respiratory
system. The range of antibiotics reported in studies evaluating
antibiotics were in agreement with the findings from studies
evaluating all drug consumption in neonates. The most
common pharmacological groups reported were Penicillin and
aminoglycosides, followed by other beta lactam antibiotics.
Ampicillin and gentamicin were the most frequently used agents
in neonates and were reported in the majority of the studies. The
detailed list of common drugs reported in the selected studies is
shown in Table 4. Five studies documented drug consumption
and its comparisons across neonatal gestational age groups
(Warrier et al., 2006; Neubert et al., 2010; Lass et al., 2011;
Goncalves et al., 2015; Suryawanshi et al., 2016).
DISCUSSION
The number of drug utilization studies in neonates is limited,
with 12 studies investigating the overall usage of drugs (all
categories) and eight studies focused solely on antibiotic usage.
The majority of the studies were carried out in Europe and
the United States, dwarfing other studies from other regions.
The possible reason for the high number of drug utilization
studies in European countries could be due to initiatives taken
by the countries in establishing research working groups on drug
utilization, in effort to assess the benefit risk of medicines. The
Task Force in Europe for Drug Development for the Young
(TEDDY) for example is one of the research working groups that
actively conduct drug utilization research to promote safe and
effective drugs in pediatrics (Sabate et al., 2014). No information
on drug utilization research working groups for other countries
was identified.
In order to perform a robust DUR, reliable information
such as cumulative data from administrative databases (local,
regional, or national) and pharmacy purchase data or pharmacy
dispensing database, patient medical records, or charts and
drug prescriptions is needed. Similar to the review conducted
by Clavenna and Bonati, the use of different data sources
contributed to the heterogeneity (study designs, sample size,
and data collected) found in this review (Clavenna and Bonati,
2009). Cohort studies have been used to study drug utilization
patterns over time, as revealed in this review (five cohort studies,
Verhamme and Sturkenboom, 2011). Due to variation in study
types (design and methods), data collected and methods used for
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reporting drug consumption, comparative evaluation of studies
was difficult.
DUR with the use of a standardized methodology (WHO
ATC/DDD) allows a researcher to compare drug use in different
countries and other levels of healthcare on an equal basis. It
must be noted that the ATC classification system is now used
as an international standard to classify drugs. DDD denotes the
average maintenance dose of the drug when used on its major
indication in adults (World Health Organization, 2003). DDD
serves as a technical unit of measurement in DUR. The issue in
assessing neonatal drug utilization patterns is the unavailability
of a common methodology for quantifying drug consumptions
as the DDDs proposed were meant for adults (Lass et al., 2011).
From the present review, only studies evaluating antibiotics
utilized ATC/DDD methods. Although the DDD methodology
is widely used in adults, its applicability in neonates is yet to
be studied or validated. This is because dosing in children is
calculated based on their body weight and for the purpose of
DDD calculation, an average of body weight for the pediatric
population needs to be assumed. However, pediatric DDDs still
remain questionable because dose recommendations in children,
especially neonates, vary according to their age and body weight
(Monnet, 2007; Liem et al., 2010a).
Other methods used for the evaluation of drug utilization
were PDD, Days of Therapy (DOT) and DU 90%. PDD denotes
an average dose prescribed according to a representative sample
of prescriptions. PDD emphasizes the amount of specific drugs
consumed (World Health Organization, 2003; Porta et al., 2012).
Technically, DOT is the number of days that at least one dose of
the drug is taken or should have been taken (Polk et al., 2007).
In other words, one DOT represents the administration of a
single agent on a given day, regardless of the number of doses
administered or dosage strength. Previous DUR suggested that
DOT methodology is useful to reflect drug usage in the pediatric
population as its calculation is not affected by the difference
between DDD and PDD or changes in WHO-assigned DDD.
Most importantly, the DOT methodology is independent of age-
or weight-related differences in dosage (Polk et al., 2007; Liem
et al., 2010b). However, the use of PDD and DOT were not
popular as only a single study evaluated antibiotic consumption
using these methods (Zingg et al., 2011; Porta et al., 2012). The
DU90% was used in four of the included studies, and it is an
essential tool to assess the quality of drug prescription. The
DU90% represents the number of drugs accounting for 90% of
drug use (Bergman et al., 1998).
Knowing the limitations of applying DDD to pediatrics,
especially neonates, three studies from India utilized WHO
core prescribing indicators for reporting drug consumption. The
WHO core prescribing indicators is a set of drug-prescribing
indicators that measure: the degree of polypharmacy; the
tendency to prescribe drugs by generic name; the overall level
of use of antibiotics and injections; and the degree to which the
prescribing practice conforms to the essential drug list, formulary
or standard treatment guideline (World Health Organization,
1993). Although these indicators were developed to evaluate the
appropriateness of drug use in outpatient health facilities, in an
effort to promote rational drug use, they have also been used
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in studies evaluating drug use for inpatient children (Woldu
et al., 2013; Ambaw and Gabriel, 2015). Nevertheless, as drug use
patterns are more complex in inpatient settings, or in specialty
outpatient clinics in referral hospitals, these indicators appear to
be less useful when applied to NICU or other neonatal wards
(World Health Organization, 1993).
The majority of the selected studies utilized a volume
unit, such as the number of prescriptions, drugs or patients,
to compute the consumption of drugs in general neonates.
Although these volume units can be used to make a national
comparison of drug consumption, none of them are applicable
for cross-national comparisons (World Health Organization,
2003). Several attempts have been made by researchers to
propose a valid and reliable methodology for drug utilization
measurement in neonates. From a pilot study in four European
children’s hospitals located in the UK, Greece and Italy, a 3-
step algorithm for reporting antimicrobial drug utilization in
pediatric patients has been produced. However, the algorithm
need to be validated in larger populations (Porta et al., 2012).
Another piece of research demonstrated that a set of neonatal
DDDs for 10 commonly used antibiotics based on an assumed
neonatal weight of 2 kg could be a useful study methodology
(Liem et al., 2010a).
The International Conference on Harmonisation Guidelines
on Clinical Investigation of Medicinal Products in the Paediatric
Population is well aware of the elevated level of clinical research
and has recommended that drug effects within different age
categories in children are studied (International Conference on
Harmonisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use, 2014). Indeed, in neonates,
pattern of drugs differs based on gestational age and this has
been documented in studies included in this review (Warrier
et al., 2006; Neubert et al., 2010; Lass et al., 2011; Goncalves
et al., 2015; Suryawanshi et al., 2016). As antibiotics are
crucial to ensure survival after a serious infection, antimicrobial
agents for systemic use (ampicillin and gentamicin) are the
most frequently used therapeutic agents in this group of
patients.
Like other systematic review, this review has its own
limitations. For example, non-English language articles on
neonatal drug utilization neonates could have been missed as
they were excluded. Secondly, although a complete search was
conducted, only studies evaluating all drug categories and the
most common therapeutic drug class were analyzed, while some
drug utilization studies on other classes were carried out in
neonates. We cannot perform a meta-analysis due to the vast
heterogeneity of the data reported, notwithstanding different
study design andmeasuring parameters. Nevertheless, in order to
enhance the quality of the review, gray literature was not included
and only the best-quality studies were evaluated for review.
CONCLUSIONS
The present review revealed that neonates are exposed to a high
number of drugs. Various methods were used to report drug
consumption in this age group. The quality assessment shows
that 45 and 40% of the included studies are classified as fair and
good quality, respectively. An equal percentage was seen in terms
of the study design used, namely prospective, cross-sectional and
retrospective studies. Up to 70% of the selected studies aimed
to describe drug consumption patterns of neonates. The best
measure of drug consumption to adequately quantify prevalence
of drug use in neonates remains to be identified, and additional
research in this field is warranted.
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